LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

METRO-BIBF: Phase II, randomised, placebo controlled, multicentre, trial of low dose (metronomic) cyclophosphamide (MCy) with or without nintedanib in relapsed ovarian cancer (ROC).

Photo by nci from unsplash

5551Background: ROC patients (pts), heavily pretreated with IV chemotherapy (CT) are a heterogenous group, median OS 3-9 mo. Oral MCy is well tolerated, avoids IV CT and has been shown… Click to show full abstract

5551Background: ROC patients (pts), heavily pretreated with IV chemotherapy (CT) are a heterogenous group, median OS 3-9 mo. Oral MCy is well tolerated, avoids IV CT and has been shown to have clin...

Keywords: phase randomised; metro bibf; roc; randomised placebo; bibf phase; mcy

Journal Title: Journal of Clinical Oncology
Year Published: 2018

Link to full text (if available)


Share on Social Media:                               Sign Up to like & get
recommendations!

Related content

More Information              News              Social Media              Video              Recommended



                Click one of the above tabs to view related content.